The novel coronavirus-triggered disease, covid 19, continues to make victims all over the world. While we are in the middle of the fourth covid wave, experts are working hard in order to find more and more viable treatments that could be able to save lives.
As you know by now, there are already many vaccines that have been deployed all over the world, but scientists are working to develop treatments as well.
Amidst the dramatic reports from all over the world triggered by the terrible disease, the US FDA saw an application coming from Merck submitted for emergency authorization – this could be the very first pill-based treatment for the deadly illness.
Quick update on state of the pandemic in the US in 4 graphs
We have clearly turned the corner on the delta surge
Now down 40% since peak a month ago
Still at high levels of infections and deaths
But good to be heading down as we head into fall and winter pic.twitter.com/uFKHcmz2Bg
— Ashish K. Jha, MD, MPH (@ashishkjha) October 10, 2021
It’s been just reported that Merck teamed up with partner Ridgeback Biotherapeutics, and had already said the following:
“data from a Phase 3 trial of the treatment, molnupiravir, an oral antiviral medicine, reduced the risk of hospitalization or death in adults at risk from severe covid 19 by 50%.”
Covid infections are rising among children
Bloomberg just revealed a terrible note.
The popular publication reports that the coronavirus infections among school-aged children in England are “high and rising.”
This is according to a major study that is likely to exacerbate concerns about the pace of the vaccine rollout.
Bloomberg notes the following:
“Prevalence of Covid-19 is growing among those aged 17 and younger, the React-1 study led by Imperial College London found.”
The official data also revealed:
“The reproduction rate in that age group was 1.18, meaning that on average every 10 young people infected is passing it on to about 12 others.”
That has driven up the national infection rate, even though the prevalence is falling in the 18-54 age group.